v3.26.1
License Agreements (Additional Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 11, 2026
Dec. 20, 2025
Nov. 03, 2025
Feb. 22, 2025
Jun. 14, 2022
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Feb. 28, 2025
Business Combination [Line Items]                  
Royalty expenses           $ 0 $ 100    
Gloperba Rest of World License Agreement [Member]                  
Business Combination [Line Items]                  
Revenue, Remaining Performance Obligation, Percentage                 50.00%
Elyxyb Rest Of World License Agreement [Member]                  
Business Combination [Line Items]                  
Revenue, Remaining Performance Obligation, Percentage                 50.00%
Tlido Rest Of World License Agreement [Member]                  
Business Combination [Line Items]                  
Aggregate Payment Of Company       $ 200,000          
Percentage of Lidocaine Topical System       1.80%          
Vivasor Datavault License Agreement [Member]                  
Business Combination [Line Items]                  
License fee payable           20,000      
Non Refundable License Fee   $ 20,000              
Royalty Payments Percentage   5.00%              
Milestone Payment   $ 2,550,000              
Non-refundable license fee Payable   120 days              
EOS Technology Holdings Patent Agreement [Member]                  
Business Combination [Line Items]                  
Purchased Asset Terms The Company is currently evaluating potential monetization strategies for the Purchased Assets, including allocation of resources, and anticipates deploying the technology within 12 to 24 months following the purchase date.                
Payment for Purchased Asset $ 2,900         2,900      
Royalty Payments Percentage 3.00%                
Romeg License Agreement [Member]                  
Business Combination [Line Items]                  
Up-front license fee         $ 2,000        
Scilex Pharma [Member] | Tlido Rest Of World License Agreement [Member]                  
Business Combination [Line Items]                  
Revenue, Remaining Performance Obligation, Percentage       50.00%          
License Agreement | Romeg License Agreement [Member]                  
Business Combination [Line Items]                  
Up-front license fee         2,000        
Payment upon the achievement of net sales         13,000        
Payments for royalties         150,000        
Non-Refundable, Non-Creditable Payment         $ 700,000        
Transfer of Common Stock Shares         22,267        
Intangible asset         $ 5,700        
Deferred consideration         $ 3,700        
Royalty expenses           200 $ 200    
Contingent consideration, liability           0   $ 0  
Datavault License Agreement [Member]                  
Business Combination [Line Items]                  
License Agreement, Description     As consideration for the license under the Datavault License Agreement, the Company agreed to pay Datavault (a) a non-refundable license fee of $10.0 million, payable in four equal installments of $2,500,000 on or before the last day of each fiscal quarter, beginning on December 31, 2025, (b) subject to achievement of certain net sales for the Licensed Product (as defined therein), up to an aggregate of $2,550,000,000, and (c) a five-percent (5%) royalty on net sales of the Product (as defined therein) during the applicable royalty term under the Datavault License Agreement.            
Aggregate net sales for the licensed product     $ 2,550,000,000            
Royalty Rate Percentage     5.00%            
License fee payable           9,500      
license Fee           $ 10,000      
Non Refundable License Fee     $ 10,000            
Datavault License Agreement [Member] | Minimum [Member]                  
Business Combination [Line Items]                  
Royalty expenses     1,000,000            
Datavault License Agreement [Member] | Four Equal Installments [Member]                  
Business Combination [Line Items]                  
License fee payable     $ 2,500,000